about
From VGKC to LGI1 and Caspr2 encephalitis: The evolution of a disease entity over timeDetection and Characterization of Autoantibodies to Neuronal Cell-Surface Antigens in the Central Nervous SystemHerpes simplex virus encephalitis is a trigger of brain autoimmunity.Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patientsAnti-N-methyl-D-aspartate receptor-mediated encephalitis in infants and toddlers: case report and review of the literature.SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study.Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis.IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis.Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patientsEncephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies.Encephalitis and AMPA receptor antibodies: Novel findings in a case series of 22 patients.Available treatment options for the management of Lambert-Eaton myasthenic syndrome.Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms.Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in miceScreening for tumours in paraneoplastic syndromes: report of an EFNS task force.Transient anti-NMDAR encephalitis in a newborn infant due to transplacental transmissionPrevalence of Intrathecal Acyclovir Resistant Virus in Herpes Simplex Encephalitis Patients.Paraneoplastic syndromes and autoimmune encephalitis: Five new things.A novel treatment-responsive encephalitis with frequent opsoclonus and teratomaInvestigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response.Determination of neuronal antibodies in suspected and definite Creutzfeldt-Jakob disease.Autoimmune Encephalitis in Postpartum Psychosis.Late-onset anti-NMDA receptor encephalitis.Clinical and Immunologic Investigations in Patients With Stiff-Person Spectrum DisorderFrequency and characteristics of isolated psychiatric episodes in anti–N-methyl-d-aspartate receptor encephalitis.A clinical approach to diagnosis of autoimmune encephalitis.3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system.Antibodies to active zone protein ERC1 in Lambert-Eaton myasthenic syndrome.Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up.Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: case report.Plasticity-related gene 5: A novel surface autoantigen in paraneoplastic cerebellar degeneration.The clinical spectrum of Caspr2 antibody-associated disease.Immunoglobulin G antibodies to the N-Methyl-D-aspartate receptor are distinct from immunoglobulin A and immunoglobulin M responses.Fatal Balamuthia mandrillaris Meningoencephalitis in the Netherlands after Travel to The Gambia.Lambert-eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel.Antibodies to N-methyl-D-aspartate and other synaptic receptors in choreoathetosis and relapsing symptoms post-herpes virus encephalitis.Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
P50
Q26739918-2FA18FA2-B828-4596-9D60-FDF7980A5824Q26746048-BBC67011-00F1-4327-9351-6C8C4FDFF684Q30574452-D2312F3C-52A9-4693-84D2-C6F9C85522FEQ30577920-994FE231-02FA-4DDB-A0C9-D1AF75BF0E9AQ30710506-800A4A2F-7098-48C3-B459-7B3EA2E1CFFEQ33306794-458F2C77-0113-4A0F-84C6-184854A23EFCQ33551430-479259C4-CEB5-4126-A6E7-F31B3A979F46Q33591024-20BD8D7A-42C3-43A4-ADB1-BE3D6EE325CCQ33645697-E10D1CA1-03C6-4F72-97E1-C67F7433682FQ34233555-5C8F151A-8038-41BD-B88F-843F3E86F7BFQ34373472-E70B25A0-C64D-4C80-B59A-48AE5A270265Q34399975-499373A3-7331-49D4-9406-569DC445DF4BQ34476604-20B74883-4AC5-4596-A285-3C46FF36D708Q34542581-CB4F50A1-29A7-4ACC-A7C0-1BEACF79F6E4Q34787804-41CC7CC6-7D9B-4881-97DB-51C906AD454FQ34842262-4C5A71BE-1FD4-4991-8DE1-3F5ED49C9AEEQ34911466-4E6C01B6-F397-42FF-A9BB-449DFFF3FB7AQ35764722-493EA793-6800-45D1-943A-C83BCFE35F35Q36015799-8659339D-225C-4775-8470-7AF51A7800A9Q36731515-426E6D18-1B0D-4518-B876-4278FE8E508AQ36763031-F214FA93-D3C6-425A-B583-6EA251315C5FQ36813361-5D463D1C-CC9C-4257-9F49-9C268B8BFD37Q36813368-6834379C-6B3F-4C93-8DB7-676F6836C0F0Q36862598-97EF8CE3-BF49-4C21-81BE-96E540ED578CQ37227023-16746F3B-9B94-4919-9059-26F0241A7235Q37250508-6E6E13D6-46C6-4791-8988-4DDF45A0DEFBQ37258132-40110650-AE36-4476-910E-B646F056BC11Q37343730-6E161B34-D602-48C0-9F33-FE363F348046Q37803410-379C98AB-9F8E-499B-95A7-1F56FC80B9E4Q38162307-8FB91B1E-93CB-4197-8AA2-75576583B92BQ39167094-5B93E6E9-EBED-47AB-963C-760C46DD1CE6Q40596493-387DC75B-1170-4A77-B7C6-765FB23D6DF1Q41860054-6CC0C0D6-CBA9-47F1-BDA0-DA86F4BB967BQ42136959-F791F540-0603-4745-9804-32279CA420CEQ42385999-4B4EFEBA-6295-499D-B596-CD3A4112AB87Q42558140-9CF04B22-EFDA-4048-8FC3-00E3292B45E8Q42584786-7769DA49-BF21-4CC1-B2BB-22207E0E4BFBQ43502163-49A85C77-47D1-4420-BACA-9D354EF4A542Q44783816-88EDE653-447A-4D02-9DD5-8C5FF86038B4Q46055747-A5060323-8236-4A3E-A3EC-21E1C2CFD177
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Maarten J. Titulaer
@ast
Maarten J. Titulaer
@en
Maarten J. Titulaer
@es
Maarten J. Titulaer
@nl
Maarten J. Titulaer
@sl
type
label
Maarten J. Titulaer
@ast
Maarten J. Titulaer
@en
Maarten J. Titulaer
@es
Maarten J. Titulaer
@nl
Maarten J. Titulaer
@sl
prefLabel
Maarten J. Titulaer
@ast
Maarten J. Titulaer
@en
Maarten J. Titulaer
@es
Maarten J. Titulaer
@nl
Maarten J. Titulaer
@sl
P106
P1153
22982086400
P21
P31
P496
0000-0002-1033-3840